ZTS
Zoetis Inc.
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · US
$75.81
−0.63%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 9.5B | 9.5B | 9.3B | 8.5B | 8.1B |
| Cost of Revenue | 2.8B | 2.8B | 2.9B | 2.7B | 2.6B |
| Gross Profit | 6.7B | 6.7B | 6.4B | 5.8B | 5.5B |
| Operating Expenses | |||||
| R&D Expense | 722.0M | 698.0M | 686.0M | 614.0M | 539.0M |
| SG&A Expense | 2.4B | 2.4B | 2.3B | 2.2B | 2.0B |
| General & Admin Expense | — | — | 2.0B | — | — |
| Selling & Marketing Expense | — | — | 302.0M | — | — |
| Other Expenses | 124.0M | — | — | — | — |
| Total Operating Expenses | 3.2B | 3.1B | 3.0B | 2.8B | 2.5B |
| Cost and Expenses | 6.0B | 5.9B | 5.9B | 5.5B | 5.2B |
| Operating Income (EBIT) | 3.5B | 3.6B | 3.4B | 3.1B | 2.9B |
| Non-Operating | |||||
| Interest Income | 72.0M | 93.0M | 106.0M | 105.0M | 50.0M |
| Interest Expense | 244.0M | 243.0M | 242.0M | 258.0M | 237.0M |
| Net Interest Income | (172.0M) | (150.0M) | (136.0M) | (153.0M) | (187.0M) |
| Other Non-Op Income/Expense | (249.0M) | (237.0M) | (259.0M) | (133.0M) | (272.0M) |
| Non-Operating Income (excl Interest) | 11.0M | 15.0M | 17.0M | (125.0M) | 35.0M |
| EBT (Pre-Tax Income) | 3.3B | 3.4B | 3.1B | 2.9B | 2.7B |
| Income Tax Expense | 656.0M | 687.0M | 637.0M | 596.0M | 545.0M |
| Bottom Line | |||||
| Net Income | 2.6B | 2.7B | 2.5B | 2.3B | 2.1B |
| Earnings from Cont. Ops | 2.6B | 2.7B | 2.5B | 2.3B | 2.1B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 2.6B | 2.7B | 2.5B | 2.3B | 2.1B |
| Per Share | |||||
| Basic EPS | $6.08 | $6.03 | $5.47 | $5.08 | $4.51 |
| Diluted EPS | $6.07 | $6.02 | $5.47 | $5.07 | $4.49 |
| Revenue Per Share | $22.79 | $21.35 | $20.38 | $18.53 | $17.23 |
| Shares | |||||
| Basic Shares Outstanding | 417.6M | 443.4M | 454.2M | 461.2M | 468.9M |
| Diluted Shares Outstanding | 417.7M | 443.8M | 454.8M | 462.3M | 470.4M |
| Profitability Metrics | |||||
| EBITDA | 3.9B | 4.1B | 3.9B | 3.7B | 3.4B |
| D&A | 364.0M | 487.0M | 497.0M | 491.0M | 465.0M |
| EBIT | 3.5B | 3.6B | 3.4B | 3.2B | 2.9B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026